Mon, Oct 20, 2014, 11:59 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

AstraZeneca PLC Message Board

hapmojong 17 posts  |  Last Activity: Jan 31, 2013 6:51 AM Member since: Jan 6, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • hapmojong by hapmojong Jan 31, 2013 6:51 AM Flag

    Today´s results are shockingly bad, and hold no prospect of better days ahead. The risks that are now precipitating into profit declines and a destruction in shareholder value were fully visible ten or more years ago. A promising pipeline grossly mismanaged. Poor acquisition choices, that missed the point, when obviously better candidates were available. Missing the opportunity to resolve the issues with Merck (read the contingent liabilities note in the 20/F) when Vioxx left Merck vulnerable. #$%$ managers who talk incessantly about people, performance, motivation, process & technology, but whose actions verge on the psychopathic. Fast forward in finance? How apt to choose a slogan based on the cassette recorder when that technology was already obsolete! McKillop, Brennan and Symonds need to hang their heads in shame for the catastrophe that their hubris, incompetence and indecision is now visiting on a once great company. AstraZeneca needed a truly visionary leader, but instead appointed men with brains of mud and feet of clay. Two have already had the truth of their capability properly judged by the public. One to go, and his day of reckoning can´t be too far away - the Americans weren´t fooled, and the Swiss are not stupid.

    Sentiment: Sell

  • Reply to

    The fuckwit departs ...

    by strangeness_and_charm Jun 7, 2007 11:22 AM
    hapmojong hapmojong Jun 15, 2007 2:22 AM Flag

    Agree completely. The man, sorry mouse, is profoundly foolish. It is amazing that someone with such poor commercial or operational capability could be in that role for so long.

    His own behaviour has poisoned the culture within Finance - it is no secret that to 'get on' at AZ, you either have to behave appallingly towards your colleagues, or if female, sleep around.

  • Reply to

    Monsanto is going to drop to

    by urlbutt Jun 24, 2002 12:33 PM
    hapmojong hapmojong Jun 24, 2002 3:41 PM Flag

    You're probably right. Roundup enterprise value is declining daily as it is consumed by generics, and by dreadful management (Argentina). Markets like Japan are being exited. Biotech business enterprise value increasingly uncertain (two billion write off - thanks, Boob!). Forget a float - look to a break up and trade sale of the two separate parts.

  • Reply to

    Monsanto: Better than God!

    by aclark2000 Mar 31, 2001 5:44 PM
    hapmojong hapmojong Apr 1, 2001 6:18 AM Flag

    Often an unmet need coincides with a profit making opportunity - do you want research into pharmaceuticals and agricultural biotech to stop because many needs are not currently met? There is a myth that the food supply would be safer if we returned to the pastoral idyll prior to the industrial revolution - the cruel reality is that much of the world's population would starve to death if this happened, and the liberal elite would find it difficult to sustain their niche diet. In fact, food scares in Europe are likely to have the effect of making much of European agriculture less intensive, leaving an opportunity for Asian and African nations to be preferred suppliers. Biotech does offer these nations a way to manage the environmental impact of agriculture in a more sustainable way than was available 50 years ago after the end of WW2 - on balance, this has got to be a good thing, would you not agree?

  • Reply to

    GUILTY AS CHARGED

    by Genes_R_Us Mar 30, 2001 10:54 AM
    hapmojong hapmojong Apr 1, 2001 6:08 AM Flag

    Actually I was trying to be ironic re application of RU, but tempers seem to be so frayed on this board that it obviously doesn't work. But my own father is 79, and I'd hate to see him harried in court - public perception is important!

  • Reply to

    GUILTY AS CHARGED

    by Genes_R_Us Mar 30, 2001 10:54 AM
    hapmojong hapmojong Mar 31, 2001 4:43 PM Flag

    So what are they gonna do to a 79 year old man? Perhpas if they spray his crop with Roundup that'll solve the problem.

  • ..........who thinks that McKillop is a fatuous, self-regarding, arrogant tosser who will probably be turfed out within two years when all the megabrand hype turns out to be empty talk? And when are they going to close those cost bases in Sweden burning a hole in the expenses (and get rid of most of the Swedish no-hopers)?

  • hapmojong by hapmojong Dec 12, 1999 4:24 AM Flag

    Losec and Zestril both come off patent in 2001 -
    probably 40-50% of turnover. What if anything is going to
    drive the share price during the period of uncertainty
    before the patent expiries, and it becomes clear whether
    it is manageable, or a disaster?

  • hapmojong by hapmojong Nov 30, 1999 7:38 PM Flag

    From yesterday's FT ;

    Companies News /
    Medical Industries

    Research may give Merck and
    Monsanto a headache
    By Victoria Griffith

    New
    research to be published on Tuesday may put two of this
    year's fastest selling new drugs, Monsanto's Celebrex
    and Merck's Vioxx, under a cloud.

    These
    so-called super aspirins may prevent the healing of
    gastro-intestinal ulcers, according to a study to be published in
    the December issue of the science journal Nature
    Medicine.

    The finding is important because the pain relievers
    are marketed as being much less harmful to the human
    digestive system than aspirin and
    ibu-profen.

    Researchers at the Veteran Affairs Medical Centre in
    California said the Cox-2 inhibitors, as Celebrex and Vioxx
    are known, prevented ulcers and wounds from healing
    by discouraging the formation of blood vessels.
    "This research is a word of caution that we need to
    study these drugs more carefully," says Andrzej
    Tarnawski, an author of the study.

    Since its American
    launch in January, Celebrex, made by Searle - Monsanto's
    pharmaceutical arm - and co-promoted by Pfizer, has brought in
    an estimated $1bn in revenues. Vioxx, the Merck
    product that was launched in the US market in August, is
    forecast to generate $400m in sales in its first five
    months.

    Monsanto and Merck have both invested heavily in the
    approval and marketing of super-aspirin products - and
    both are currently working on successors to Vioxx and
    Celebrex.

    Celebrex is Monsanto's most valuable drug by far. While
    Merck has other best-sellers, the company is counting
    on Vioxx to bridge a new product pipeline gap that
    may emerge over the next few years as US patents
    expire on some of its most important products, including
    Vasotec and Mevacor.

    Merck said yesterday that its
    own large-scale clinical trial, which led to the
    approval of the drug by the US Food & Drug Administration,
    should take precedence over the Nature Medicine
    research, which was a laboratory study.

    "About 15%
    of the people in our clinical trial had the
    beginnings of ulcers and Vioxx did not worsen their
    condition any more than the placebo," said Dr Thomas Simon,
    head of gastro-intestinal research for
    Merck.

    Scientists have theorised that the super-aspirins have fewer
    gastro-intestinal side effects because they are more selective.
    While both damp the creation of "Cox" enzymes, which
    are associated with pain, super-aspirin affects only
    "Cox-2". "Cox-1", targeted by traditional pain relievers,
    is thought to be the cox enzyme associated with
    stomach upset. According to Stanford University,
    traditional pain relievers caused 16,500 deaths last year
    because of gastro-intestinal complications.

    Mr
    Tarnawski and his colleagues argue that the inhibition of
    blood vessel creation is the same mechanism that makes
    the Cox-2 inhibitors effective against tumour
    formation. Because tumours need oxygen and nutrients to
    survive, a reduction in blood flow can be a potent anti-
    cancer tool.

    Searle has filed with the FDA to
    receive approval for Celebrex for the prevention of a
    certain type of tumour associated with colon cancer.
    Merck has conducted studies that show Vioxx may also be
    useful for tumour inhibition.

  • Reply to

    Shapiro to go

    by forty_plus Oct 1, 1999 12:14 PM
    hapmojong hapmojong Oct 5, 1999 1:37 AM Flag

    Merck has much more room for manouevre than MTC/PFE. That's a significant competitive advantage.

  • Reply to

    Thanks Again CD

    by Paradoody Jul 27, 1999 1:39 PM
    hapmojong hapmojong Jul 29, 1999 12:42 AM Flag

    DD - no way, on antitrust grounds
    (Pioneer)
    AHP - no way, they want to get out of ag - AmCy is on
    the block
    RP/Agrevo - no way, they have 2-3 years
    of FrancoGerman warfare ahead of them
    Dow - no
    way, too weak / pathetic
    Novartis - maybe, but
    would be the kiss of death
    Bayer - maybe, but
    similar to Novartis
    AZN - maybe, if Ag/Ph
    separate

    Views?

  • Reply to

    In short AZN executes proficiently...

    by mmm321 Jul 20, 1999 8:55 PM
    hapmojong hapmojong Jul 23, 1999 6:12 AM Flag

    This stock won't move in the short term until
    they do something with agrochemicals, and not until
    2001 and the "sword of damocles" of the uncertainty
    surrounding patent expiries of both Losec and Zestril is
    resolved.

    That is - unless they do a really good deal for
    agchem, and manage to commercialise their own pipeline
    and / or flesh it out with acquisitions / licensing
    deals.

    What are the options for agchem? My view, in
    descending order - 1. Dupont or Novartis, 2. Monsanto or 3.
    Bayer.

    What are the options for pharma - well, they should
    definitely have gone for Sugen, and probably Centocor. Two
    missed opportunities! Difficult to find more attractive
    candidates in the current envvironment.

    Views?

  • hapmojong by hapmojong May 30, 1999 8:27 PM Flag

    Any thoughts out there on the options for
    Agrochemicals and likely timimg? Good article from Bloomberg
    follows.


    AstraZeneca, Novartis May Sell Agrochemical Units, People Say

    London, May 28 (Bloomberg) -- AstraZeneca Plc and
    Novartis
    AG, the world's biggest drug companies, are each
    considering
    selling their agrochemicals divisions to focus on more
    profitable
    pharmaceuticals, people close to the discussions said. The people
    said the talks between the companies and their
    advisers are still at an early stage and that all options
    are under consideration, including spinning off the
    units to shareholders or selling them to competitors or
    buyout firms.

    The talks come at a time when
    European drug companies in
    particular are under
    pressure to expand earnings in their more
    profitable
    drug divisions. While AstraZeneca and Novartis
    have
    leading positions in crop-protection -- Novartis was No.
    1 and
    AstraZeneca No. 5 in 1998 sales -- the $28
    billion industry is
    suffering from sluggish growth,
    and analysts see no compelling
    reason for either
    to hang on to agrochemicals.

    ``The question
    is: Do they invest in agrochemicals when
    the
    returns are half that of pharmaceuticals or do they
    divest and
    use the proceeds in pharmaceuticals?,''
    said Nigel Barnes, a
    pharmaceuticals analyst with
    Merrill Lynch & Co.

    Both companies declined to
    comment on any talks, although
    spokesmen for both said
    they are always reviewing options to
    enhance
    corporate prospects.

    Antitrust Review
    The
    problems of splitting of such large divisions are
    many
    and would take months to address, the people close to
    the talks
    said.

  • Attached is a synopsis of CNBC on MTC/DD. What
    are people's thoughts on the other possible suitors -
    Zeneca, Novartis, WLA?

    Greg Miles MTC/DD


    Price of both have fallen quite a bit from 52 week
    highs

    Merger may not get the price up


    MTC/AHP merger attempt fell victim to CEO Egos


    Several mating dances, but other mergers (AHP/SBH,
    GLX/SBH) have had similar problems

    Combined
    company would be a big force

    30% of resources
    would be in Life Sciences in Pharma and AgBio, which
    would be big change for DD, who is mostly concentrated
    in Chemicals and Plastics. DD would also get
    Celebrex

    The AgBio would be a powerhouse, but
    pharmaceuticals still wouldn't have critical mass.

    There
    are problems however

    MTC may want too much
    control, and money is saved by consolidation

    DD is
    selling at a lower premium, so merger would be dilutive
    for many years

    Other MTC suitors include
    Novartis, ZEN, WLA

  • Reply to

    this stock is going to 25$$$$$ there is

    by amrepasky Jan 14, 1999 10:20 PM
    hapmojong hapmojong Jan 14, 1999 10:24 PM Flag

    As a long term biotech investor, I sincerely hope
    that the shorts lost their pants on this one. It's
    about time that the parasitic greed merchants with no
    idea of real value took a hiding. Go and find another
    sector to wreck.

  • Reply to

    Gap Open Tomorrow

    by longholler Jan 14, 1999 3:46 PM
    hapmojong hapmojong Jan 14, 1999 7:07 PM Flag

    ......is +265% in 24hrs long term?

  • hapmojong by hapmojong Jan 6, 1999 11:11 PM Flag

    Glaxo could only acquire Zeneca through a hostile
    takeover, which would be messy and unpleasant, but which
    would also, more importantly, entail a reasonable
    premium to the current share price of Zeneca. They would
    then have to write off goodwill on acquisition, which
    would probably be a charge to P&L of over GBP1Bn over a
    20 year period. Does anyone seriously think that
    they would countenance this?

AZN
67.95+0.14(+0.21%)Oct 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.